Literature DB >> 35465341

Cardiac disorders worsen the final outcome in myasthenic crisis undergoing non-invasive mechanical ventilation: a retrospective 20-year study from a single center.

Erika Iori1, Alessandra Ariatti1, Marco Mazzoli1, Elisabetta Bastia2, Manuela Gozzi3, Virginia Agnoletto2, Alessandro Marchioni4, Giuliana Galassi1.   

Abstract

The study was performed to evaluate the impact of cardiological disorders on the outcome of myasthenic crisis (MC) requiring ventilation. The study includes 90 cases admitted to the Neurology Unit of Modena, Italy (January 2000 - September 2020). All patients were eligible for a non-invasive ventilation (NIV) trial. We analyzed the effect of cardiac comorbidities on the outcomes, which were the need of invasive ventilation, the risk tracheostomy for weaning failure and the duration of intensive care unit (ICU) stay Females were 58.9% and males 41.1%. Median age at diagnosis was 59 and at MC was 65. Patients were classified as early (EOMG) or late (LOMG), 34.4 and 65.6% respectively, according to age above or below 50; 85% of patients were anti- AChR antibody positive. Hypertension and cardiac diseases occurred at the diagnosis in 61 and 44.4%, respectively. Invasive mechanical ventilation (MV) was needed in 34% of cases. Nine subjects (10%) underwent tracheostomy because of weaning failure. Independent predictors of NIV failure were atrial fibrillation (AF), either parossistic or persistent (OR 3.05, p < 0.01), hypertensive cardiopathy (HHD) (OR 2.52, p < 0.01) and ischaemic heart disease (IHD) (OR 3.08, p < 0.01). Hypertension (HT) had no statistical effect on the outcomes. HHD was a predictor of weaning failure (OR 4.01, p = 0.017). Our study shows that HHD, AF and IHD increase the risk of NIV failure in MC receiving ventilation. ©2022 Gaetano Conte Academy - Mediterranean Society of Myology.

Entities:  

Keywords:  atrial fibrillation; hypertensive heart disease; ischaemic cardiopathy; mechanical ventilation; myasthenic crisis

Mesh:

Year:  2022        PMID: 35465341      PMCID: PMC9004337          DOI: 10.36185/2532-1900-064

Source DB:  PubMed          Journal:  Acta Myol        ISSN: 1128-2460


  45 in total

1.  Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis.

Authors:  Jorge Enrique Machado-Alba; Luis Felipe Calvo-Torres; Andrés Gaviria-Mendoza; César Augusto MejíA-Vélez
Journal:  Muscle Nerve       Date:  2017-03-23       Impact factor: 3.217

2.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Roberto M Lang; Luigi P Badano; Victor Mor-Avi; Jonathan Afilalo; Anderson Armstrong; Laura Ernande; Frank A Flachskampf; Elyse Foster; Steven A Goldstein; Tatiana Kuznetsova; Patrizio Lancellotti; Denisa Muraru; Michael H Picard; Ernst R Rietzschel; Lawrence Rudski; Kirk T Spencer; Wendy Tsang; Jens-Uwe Voigt
Journal:  J Am Soc Echocardiogr       Date:  2015-01       Impact factor: 5.251

Review 3.  Hypertension and Heart Failure.

Authors:  Jeremy Slivnick; Brent C Lampert
Journal:  Heart Fail Clin       Date:  2019-07-31       Impact factor: 3.179

4.  Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases.

Authors:  Bernhard Neumann; Klemens Angstwurm; Philipp Mergenthaler; Siegfried Kohler; Silvia Schönenberger; Julian Bösel; Ursula Neumann; Amelie Vidal; Hagen B Huttner; Stefan T Gerner; Andrea Thieme; Andreas Steinbrecher; Juliane Dunkel; Christian Roth; Haucke Schneider; Eik Schimmel; Hannah Fuhrer; Christine Fahrendorf; Anke Alberty; Jan Zinke; Andreas Meisel; Christian Dohmen; Henning R Stetefeld
Journal:  Neurology       Date:  2019-12-04       Impact factor: 9.910

Review 5.  Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

Authors:  A Jaretzki; R J Barohn; R M Ernstoff; H J Kaminski; J C Keesey; A S Penn; D B Sanders
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

Review 6.  Myasthenia gravis and risks for comorbidity.

Authors:  N E Gilhus; A Nacu; J B Andersen; J F Owe
Journal:  Eur J Neurol       Date:  2014-10-30       Impact factor: 6.089

7.  Molecular Mechanisms of Diaphragm Myopathy in Humans With Severe Heart Failure.

Authors:  Norman Mangner; Jens Garbade; Estelle Heyne; Marloes van den Berg; Ephraim B Winzer; Jennifer Hommel; Marcus Sandri; Joanna Jozwiak-Nozdrzykowska; Anna L Meyer; Sven Lehmann; Clara Schmitz; Edoardo Malfatti; Michael Schwarzer; Coen A C Ottenheijm; T Scott Bowen; Axel Linke; Volker Adams
Journal:  Circ Res       Date:  2021-02-04       Impact factor: 17.367

Review 8.  Diaphragm abnormalities in heart failure and aging: mechanisms and integration of cardiovascular and respiratory pathophysiology.

Authors:  Rachel C Kelley; Leonardo F Ferreira
Journal:  Heart Fail Rev       Date:  2017-03       Impact factor: 4.214

Review 9.  Heart-lung interactions during mechanical ventilation: the basics.

Authors:  Syed S Mahmood; Michael R Pinsky
Journal:  Ann Transl Med       Date:  2018-09

10.  A study of comorbidities in myasthenia gravis.

Authors:  Usha K Misra; Jayantee Kalita; Varun K Singh; Surendra Kumar
Journal:  Acta Neurol Belg       Date:  2019-04-10       Impact factor: 2.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.